Evidence-Based Complementary and Alternative Medicine

Copyright © 2013 Nur Akmal Ishak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. H. Pareek, S. Sharma, B. S. Khajja, K. Jain, and G. C. Jain, “Evaluation of hypoglycemic and anti-hyperglycemic potential of Tridax procumbens (Linn.),” BMC Complementary and Alternative Medicine, vol. 9, article 48, 2009. View at Publisher · View at Google Scholar · View at Scopus
2. X. K. Zheng, Y. J. Li, L. Zhang, W. S. Feng, and X. Zhang, “Antihyperglycemic activity of Selaginella tamariscina (Beauv.) Spring,” Journal of Ethnopharmacology, vol. 133, no. 2, pp. 531–537, 2011. View at Publisher · View at Google Scholar · View at Scopus
3. H. E. Lebovitz and M. A. Banerji, “Treatment of insulin resistance in diabetes mellitus,” European Journal of Pharmacology, vol. 490, no. 1–3, pp. 135–146, 2004. View at Publisher · View at Google Scholar · View at Scopus
4. Y. Wang, J. Yu, C. Zhang et al., “Influence of flavonoids from Phellinus igniarius on sturgeon caviar: antioxidant effects and sensory characteristics,” Food Chemistry, vol. 131, no. 2, pp. 206–210, 2012. View at Google Scholar
5. D. K. Patel, R. Kumar, D. Laloo, and S. Hemalatha, “Diabetes mellitus: an overview on its pharmacological aspects and reported medicinal plants having antidiabetic activity,” Asian Pacific Journal of Tropical Biomedcine, vol. 4, no. 3, pp. 411–420, 2012. View at Google Scholar
6. K. Srinivasan, B. Viswanad, L. Asrat, C. L. Kaul, and P. Ramarao, “Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening,” Pharmacological Research, vol. 52, no. 4, pp. 313–320, 2005. View at Publisher · View at Google Scholar · View at Scopus
7. D. S. Prasad, Z. Kabir, A. K. Dash, and B. C. Das, “Abdominal obesity, an independent cardiovascular risk factor in Indian subcontinent: a clinico epidemiological evidence summary,” Journal of Cardiovascular Disease Research, vol. 32, no. 2, pp. 199–205, 2011. View at Google Scholar
8. X. Zheng, L. Zhang, W. Wang, Y. Wu, Q. Zhang, and W. Feng, “Anti-diabetic activity and potential mechanism of total flavonoids of Selaginella tamariscina (Beauv.) Spring in rats induced by high fat diet and low dose STZ,” Journal of Ethnopharmacology, vol. 137, no. 3, pp. 662–668, 2012. View at Google Scholar
9. S. M. Clee and A. D. Attie, “The genetic landscape of type-2 diabetes in mice,” Endocrinology Reviews, vol. 28, no. 2, pp. 48–83, 2006. View at Google Scholar
10. P. Masiello, “Animal models of type-2 diabetes with reduced pancreatic β-cell mass,” The International Journal of Biochemistry and Cell Biology, vol. 38, no. 9, pp. 873–893, 2006. View at Google Scholar
11. M. D. Mythili, R. Vyas, G. Akila, and S. Gunasekaran, “Effect of Streptozotocin on the ultrastructure of rat pancreatic islets,” Microscopy Research and Technique, vol. 63, no. 5, pp. 274–281, 2004. View at Publisher · View at Google Scholar · View at Scopus
12. E. Shafrir, “Diabetes in animals: contribution to the understanding of diabetes by study of its etiophatology in animal models,” in Diabetes Mellitus, D. Porte, R. S. Sherwin, and A. Baron, Eds., pp. 231–255, McGraw-Hill, New York, NY, USA, 2003. View at Google Scholar
13. R. H. Unger, G. O. Clark, P. E. Scherer, and L. Orci, “Lipid homeostasis, lipotoxicity and the metabolic syndrome,” Biochimica et Biophysica Acta, vol. 1801, no. 3, pp. 209–214, 2010. View at Publisher · View at Google Scholar · View at Scopus
14. Y. Zhang, X. Li, D. Zou et al., “Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 7, pp. 2559–2565, 2008. View at Publisher · View at Google Scholar · View at Scopus
15. F. Franconi, G. Seghieri, S. Canu, E. Straface, I. Campesi, and W. Malorni, “Are the available experimental models of type 2 diabetes appropriate for a gender perspective?” Pharmacological Research, vol. 57, no. 1, pp. 6–18, 2008. View at Publisher · View at Google Scholar · View at Scopus
16. K. Sahin, M. Onderci, M. Tuzcu et al., “Effect of chromium on carbohydrate and lipid metabolism in a rat model of type 2 diabetes mellitus: the fat-fed, streptozotocin-treated rat,” Metabolism, vol. 56, no. 9, pp. 1233–1240, 2007. View at Publisher · View at Google Scholar · View at Scopus
17. S. Zhao, Y. Chu, C. Zhang et al., “Diet-induced central obesity and insulin resistance in rabbits,” Journal of Animal Physiology and Animal Nutrition, vol. 92, no. 1, pp. 105–111, 2008. View at Google Scholar
18. S. Bastaki, “Diabetes mellitus and its treatment,” International Journal of Diabetes and Metabolism, vol. 13, no. 3, pp. 111–134, 2005. View at Google Scholar · View at Scopus
19. J. G. Schier, O. N. Hirsch, J. Chu, S. McLaughlin, P. McKinney, and C. Crandall, “Octreotide as antidote for sulfonylurea-induced hypoglycemia,” Annals of Emergency Medicine, vol. 37, no. 4, pp. 417–418, 2001. View at Google Scholar · View at Scopus
20. C. M. Nzerue, J. Thomas, J. Volcy, and T. Edeki, “Use of octreotide to treat prolonged sulfonylurea-induced hypoglycemia in a patient with chronic renal failure,” International Journal of Artificial Organs, vol. 26, no. 1, pp. 86–89, 2003. View at Google Scholar · View at Scopus
21. R. E. Amori, J. Lau, and A. G. Pittas, “Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis,” Journal of the American Medical Association, vol. 298, no. 2, pp. 194–206, 2007. View at Publisher · View at Google Scholar · View at Scopus
22. International Diabetes Federation, 2009, https://www.idf.org/latest-diabetes-figures-paint-grim-global-picture.
23. H. Lü, J. Chen, W. L. Li et al., “Hypoglycemic and hypolipidemic effects of the total triterpene acid fraction from Folium Eriobotryae,” Journal of Ethnopharmacology, vol. 122, no. 3, pp. 486–491, 2009. View at Publisher · View at Google Scholar · View at Scopus
24. W. L. Li, H. C. Zheng, J. Bukuru, and N. De Kimpe, “Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus,” Journal of Ethnopharmacology, vol. 92, no. 1, pp. 1–21, 2004. View at Publisher · View at Google Scholar · View at Scopus
25. A. Ravi Kumar, S. Ponnusamy, R. Ravindran, S. Zinjarde, and S. Bhargava, “Evaluation of traditional Indian antidiabetic medicinal plants for human pancreatic amylase inhibitory effect in vitro,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 515647, 10 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
26. N. Malviya, S. Jain, and S. Malviya, “Antidiabetic potential of medicinal plants,” Acta Poloniae Pharmaceutica, vol. 67, no. 2, pp. 113–118, 2010. View at Google Scholar · View at Scopus
27. S. H. Jung, H. J. Seol, S. J. Jeon, K. H. Son, and J. R. Lee, “Insulin-sensitizing activities of tanshinones, diterpene compounds of the root of Salvia miltiorrhiza Bunge,” Phytomedicine, vol. 16, no. 4, pp. 327–335, 2009. View at Publisher · View at Google Scholar · View at Scopus
28. R. Dheer and P. Bhatnagar, “A study of the antidiabetic activity of Barleria prionitis Linn,” Indian Journal of Pharmacology, vol. 42, no. 2, pp. 70–73, 2010. View at Publisher · View at Google Scholar · View at Scopus
29. R. Randhir and K. Shetty, “Mung beans processed by solid-state bioconversion improves phenolic content and functionality relevant for diabetes and ulcer management,” Innovative Food Science and Emerging Technologies, vol. 8, no. 2, pp. 197–204, 2007. View at Publisher · View at Google Scholar · View at Scopus
30. I. M. Firdaus, A. Nur Ashikin Psyquay, S. Ghizan, and I. Maznah, “Anthesis and flower visitors in Curculigo latifolia Dryand,” Journal of Biology and Life Sciences, vol. 1, no. 1, pp. 13–15, 2010. View at Google Scholar
31. O. H. Chooi, Tumbuhan Liar: khasiat Ubatan Dan Kegunaan Lain, Utusan Publications and Distributors Sendirian Berhad, Kuala Lumpur, Malaysia, 2006.
32. R. Kant, “Sweet proteins—potential replacement for artificial low calorie sweeteners,” Nutrition Journal, vol. 4, article 5, 2005. View at Publisher · View at Google Scholar · View at Scopus
33. A. Shimizu-Ibuka, Y. Morita, T. Terada et al., “Crystal structure of neoculin: insights into its sweetness and taste-modifying activity,” Journal of Molecular Biology, vol. 359, no. 1, pp. 148–158, 2006. View at Publisher · View at Google Scholar · View at Scopus
34. B. E. Levin, S. Hogan, and A. C. Sullivan, “Initiation and perpetuation of obesity and obesity resistance in rats,” American Journal of Physiology, vol. 256, no. 3, pp. 766–771, 1989. View at Google Scholar · View at Scopus
35. M. K. Tuck, D. W. Chan, D. Chia et al., “Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group,” Journal of Proteome Research, vol. 8, no. 1, pp. 113–117, 2009. View at Publisher · View at Google Scholar · View at Scopus
36. T. Y. Reuter, “Diet-induced models for obesity and type 2 diabetes,” Drug Discovery Today, vol. 4, no. 1, pp. 3–8, 2007. View at Publisher · View at Google Scholar · View at Scopus
37. Z. S. Warwick, S. J. Synowski, and K. R. Bell, “Dietary fat content affects energy intake and weight gain independent of diet caloric density in rats,” Physiology and Behavior, vol. 77, no. 1, pp. 85–90, 2002. View at Publisher · View at Google Scholar · View at Scopus
38. M. N. Chatterjee and R. Shinde, Text Book of Medical Biochemistry, Jaypee Brothers, 2002.
39. N. Kumar and C. S. Dey, “Metformin enhances insulin signalling in insulin-dependent and -independent pathways in insulin resistant muscle cells,” British Journal of Pharmacology, vol. 137, no. 3, pp. 329–336, 2002. View at Publisher · View at Google Scholar · View at Scopus
40. B. Rangachari and I. Savarimuthu, “Antidiabetic and Hypolipidemic effect of methanol extract of Lippia nodiflora L. in streptozotocin induced diabetic rats,” Asian Pacific Journal of Tropical Biomedicine, vol. 1, no. 1, pp. 30–36, 2011. View at Google Scholar
41. H. Jouad, A. Lemhadri, M. Maghrani, N. A. Zeggwagh, and M. Eddouks, “Cholesterol-lowering activity of the aqueous extract of Spergularia purpurea in normal and recent-onset diabetic rats,” Journal of Ethnopharmacology, vol. 87, no. 1, pp. 43–49, 2003. View at Publisher · View at Google Scholar · View at Scopus
42. Y. Li, P. Wang, Y. Zhuang et al., “Activation of AMPK by berberine promotes adiponectin multimerization in 3T3-L1 adipocytes,” FEBS Letters, vol. 585, no. 12, pp. 1735–1740, 2011. View at Publisher · View at Google Scholar · View at Scopus
43. V. Poitout and R. P. Robertson, “Minireview: secondary β-cell failure in type 2 diabetes—a convergence of glucotoxicity and lipotoxicity,” Endocrinology, vol. 143, no. 2, pp. 339–342, 2002. View at Publisher · View at Google Scholar · View at Scopus
44. P. Bansal, P. Paul, J. Mudgal et al., “Antidiabetic, antihyperlipidemic and antioxidant effects of the flavonoid rich fraction of Pilea microphylla (L.) in high fat diet/streptozotocin-induced diabetes in mice,” Experimental and Toxicologic Pathology, vol. 64, pp. 651–658, 2012. View at Publisher · View at Google Scholar · View at Scopus
45. S. Frojdo, C. Durand, L. Molin et al., “Phosphoinositide 3-kinase as a novel functional target for the regulation of the insulin signaling pathway by SIRT1,” Molecular and Cellular Endocrinology, vol. 335, no. 2, pp. 166–176, 2011. View at Google Scholar
46. Y. B. Lombardo and A. G. Chicco, “Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review,” Journal of Nutritional Biochemistry, vol. 17, no. 1, pp. 1–13, 2006. View at Publisher · View at Google Scholar · View at Scopus
47. A. S. Rossi, Y. B. Lombardo, and A. G. Chicco, “Lipogenic enzyme activities and glucose uptake in fat tissue of dyslipemic, insulin-resistant rats: effects of fish oil,” Nutrition, vol. 26, no. 2, pp. 209–217, 2010. View at Publisher · View at Google Scholar · View at Scopus
48. A. Gomes, J. R. Vedasiromoni, M. Das, R. M. Sharma, and D. K. Ganguly, “Anti-hyperglycemic effect of black tea (Camellia sinensis) in rat,” Journal of Ethnopharmacology, vol. 45, no. 3, pp. 223–226, 1995. View at Publisher · View at Google Scholar · View at Scopus
49. A. S. Shingo, T. Kanabayashi, T. Murasea, and S. Kito, “Cognitive decline in STZ-3V rats is largely due to dysfunctional insulin signaling through the dentate gyrus,” Behavioural Brain Research, vol. 229, no. 9, pp. 378–383, 2012. View at Google Scholar
50. B. Yang, L. Chen, Y. Qian et al., “Changes of skeletal muscle adiponectin content in diet-induced insulin resistant rats,” Biochemical and Biophysical Research Communications, vol. 341, no. 1, pp. 209–217, 2006. View at Publisher · View at Google Scholar · View at Scopus
51. S. Bolkent, R. Yanardag, S. Bolkent, and M. M. Döger, “Beneficial effects of combined treatment with niacin and chromium on the liver of hyperlipemic rats,” Biological Trace Element Research, vol. 101, no. 3, pp. 219–229, 2004. View at Publisher · View at Google Scholar · View at Scopus
52. M. Sugano, H. Yamato, T. Hayashi et al., “High-fat diet in low-dose-streptozotocin-treated heminephrectomized rats induces all features of human type 2 diabetic nephropathy: a new rat model of diabetic nephropathy,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 16, no. 7, pp. 477–484, 2006. View at Publisher · View at Google Scholar · View at Scopus
53. M. Rakhshandehroo, B. Knoch, M. Müller, and S. Kersten, “Peroxisome proliferator-activated receptor alpha target genes,” PPAR Research, vol. 2010, Article ID 612089, 20 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
54. C. J. Rhodes and M. F. White, “Molecular insights into insulin action and secretion,” European Journal of Clinical Investigation, vol. 32, no. 3, pp. 3–13, 2002. View at Google Scholar · View at Scopus
55. J. Palsgaard, A. E. Brown, M. Jensen, R. Borup, M. Walker, and P. De Meyts, “Insulin-like growth factor I (IGF-I) is a more potent regulator of gene expression than insulin in primary human myoblasts and myotubes,” Growth Hormone and IGF Research, vol. 19, no. 2, pp. 168–178, 2009. View at Publisher · View at Google Scholar · View at Scopus
56. S. Teppala and A. Shankar, “Association between serum IGF-1 and diabetes among U.S. adults,” Diabetes Care, vol. 33, no. 10, pp. 2257–2259, 2010. View at Publisher · View at Google Scholar · View at Scopus
57. Y. Wang, D. Zhang, Y. Liu et al., “Association study of the single nucleotide polymorphisms in adiponectin-associated genes with type 2 diabetes in Han Chinese,” Journal of Genetics and Genomics, vol. 36, no. 7, pp. 417–423, 2009. View at Publisher · View at Google Scholar · View at Scopus
58. U. Petersson, C. J. Östgren, L. Brudin, K. Brismar, and P. M. Nilsson, “Low levels of insulin-like growth-factor-binding protein-1 (IGFBP-1) are prospectively associated with the incidence of type 2 diabetes and impaired glucose tolerance (IGT): The Söderåkra Cardiovascular Risk Factor Study,” Diabetes and Metabolism, vol. 35, no. 3, pp. 198–205, 2009. View at Publisher · View at Google Scholar · View at Scopus
59. J. Pita, A. Panadero, L. Soriano-Guillén, E. Rodríguez, and A. Rovira, “The insulin sensitizing effects of PPAR-γ agonist are associated to changes in adiponectin index and adiponectin receptors in Zucker fatty rats,” Regulatory Peptides, vol. 174, no. 7, pp. 18–25, 2012. View at Google Scholar
60. M. Kuroda, Y. Mimaki, S. Honda, H. Tanaka, S. Yokota, and T. Mae, “Phenolics from Glycyrrhiza glabra roots and their PPAR-γ ligand-binding activity,” Bioorganic and Medicinal Chemistry, vol. 18, no. 2, pp. 962–970, 2010. View at Publisher · View at Google Scholar · View at Scopus
61. T. Kadowaki and T. Yamauchi, “Adiponectin and adiponectin receptors,” Endocrine Reviews, vol. 26, no. 3, pp. 439–451, 2005. View at Publisher · View at Google Scholar · View at Scopus
62. B. Gross and B. Staels, “PPAR agonists: multimodal drugs for the treatment of type-2 diabetes,” Best Practice and Research in Clinical Endocrinology and Metabolism, vol. 21, no. 4, pp. 687–710, 2007. View at Publisher · View at Google Scholar · View at Scopus
63. F. Lalloyer, B. Vandewalle, F. Percevault et al., “Peroxisome proliferator-activated receptor α improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets,” Diabetes, vol. 55, no. 6, pp. 1605–1613, 2006. View at Publisher · View at Google Scholar · View at Scopus
64. B. Staels and J. C. Fruchart, “Therapeutic roles of peroxisome proliferator-activated receptor agonists,” Diabetes, vol. 54, no. 8, pp. 2460–2470, 2005. View at Publisher · View at Google Scholar · View at Scopus
65. K. Ravnskjaer, M. Boergesen, B. Rubi et al., “Peroxisome proliferator-activated receptor α (PPARα) potentiates, whereas PPARγ attenuates, glucose-stimulated insulin secretion in pancreatic β-cells,” Endocrinology, vol. 146, no. 8, pp. 3266–3276, 2005. View at Publisher · View at Google Scholar · View at Scopus
66. G. R. Hajer, T. W. Van Haeften, and F. L. J. Visseren, “Adipose tissue dysfunction in obesity, diabetes, and vascular diseases,” European Heart Journal, vol. 29, no. 24, pp. 2959–2971, 2008. View at Publisher · View at Google Scholar · View at Scopus